Eli Lilly and Co. has struck another major China partnership, signing a discovery-stage collaboration with Beijing-based ...

Merck & Co. Inc.’s positive top-line data from the pivotal phase IIb/III Brunello trial with remigromig in adults with ...

From the start, Heidi Overton’s confirmation hearing as U.S. FDA commissioner was shadowed by the broken promises Robert Kennedy made to the Senate Health, Education, Labor and Pensions Committee in ...

Finnish newco Kasvu Therapeutics has raised €30 million (US$34.4 million) in a series A financing to take forward novel small ...

Enveda Therapeutics Inc. has doubled its valuation to approximately $2 billion in a $311 million series E financing, led by ...

Even though the molecular and clinical genetics devices panel of the medical devices advisory committee for the U.S. FDA ...

Another long-acting insulin has cleared the U.S. FDA’s hurdle, with Eli Lilly and Co.’s Onswik (insulin efsitora alfa-gobe) winning approval for the type 2 diabetes community.

Despite considerable advances in diagnosis, new gene-modifying modalities and significant regulatory inducements, there remains a long tail of rare diseases that are below the threshold required for ...

Privately held Atavistik Bio Inc. chalked a research collaboration with Roche AG to discover and develop small-molecule therapeutics against multiple targets for cardiovascular, renal and metabolic ...

In the face of immediate bipartisan backlash from key U.S. lawmakers and the research community, the Trump administration is reportedly backing away from a proposed executive order giving the White ...

In its second major collaboration announced this year, AI-focused Earendil Labs is pairing up with Roche Holding AG’s Genentech unit in a discovery deal aimed at developing bispecific antibody ...

Nearly two years after licensing Relay Therapeutics Inc.’s oral small-molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), lirafugratinib, Elevar Therapeutics Inc. won U.S. FDA approval ...